Trials / Completed
CompletedNCT02916706
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 254 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneligliptin 20mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-08-14
- First posted
- 2016-09-27
- Last updated
- 2026-01-06
- Results posted
- 2022-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02916706. Inclusion in this directory is not an endorsement.